The FDA has accepted for Priority Review the BLA for tividenofusp alfa for the treatment of Hunter syndrome, also known as MPS II.

The ongoing Monsoon Session of Bihar Assembly witnessed another stormy session today when Chief Minister Nitish Kumar called Leader of Opposition in Bihar Assembly Tejashwi Yadav ‘Bachcha’ (a child) ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Pakistan PM Shehbaz Sharif reviewed safety measures for Chinese citizens in CPEC projects. China urged Pakistan to act ...

Beat the Dubai heat with these cool bars and refreshing drinks The city’s a little quieter. The pace has slowed. But staying ...

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...

Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...